Luye Pharma Group
Global pharmaceutical company focused on long-acting and transdermal delivery systems in neurology, oncology and other areas.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 3 · Recruiting · Relapsed Small Cell Lung Cancer
Study of LY01610 in Patients With Recurrent Small Cell Lung CancerPhase 3 · Recruiting · Relapsed Small Cell Lung Cancer
Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive DyskinesiaPhase 1 · Recruiting · Tardive Dyskinesia (TD)
A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020Phase 1 · Recruiting · Schizophrenia
First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.Phase 1 · Recruiting · Advanced Solid Tumor
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017Phase 1 · Not Yet Recruiting · Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis
Selected patent records
risperidone · Expires 2026-06-26
US 10058554risperidone · Expires 2026-09-26
US 9597402risperidone · Expires 2026-09-26
US 11110093risperidone · Expires 2026-11-05
US 8221778risperidone · Expires 2027-11-12
US 8741327risperidone · Expires 2027-11-12
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/luye-pharma-group/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.